Both analytes were described to relate to cardiotoxicity either in early TNBC patients under epirubicin/cyclophosphamide-docetaxel neoadjuvant chemotherapy [188] or in HER2-positive BC patients who received anthracycline-based chemotherapy [189]. This evidence concerns the gene ERBB2 and breast cancer.